SkinBioTherapeutics plc (AIM:SBTX)

Revenue by Segment

Financials in millions GBP. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017	Jun 30, 2016
Identifying and Developing Formulations	4.64M	1.21M	132.06K	74.76K						2.77K
Identifying and Developing Formulations Growth	283.74%	815.26%	76.64%	-						-
Total	4.64M	1.21M	132.06K	74.76K						2.77K
Total Growth	283.74%	815.26%	76.64%	-						-

Revenue by Geography

Financials in millions GBP. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017	Jun 30, 2016
United Kingdom	3.12M	990.35K	118.92K	57.69K						2.77K
United Kingdom Growth	215.46%	732.78%	106.15%	-						-
Europe	1.22M	102.68K	3.86K	-						-
Europe Growth	1090.72%	2559.31%	-	-						-
United States of America	147.49K	35.36K	9.28K	17.07K						-
United States of America Growth	317.08%	281.27%	-45.68%	-						-
Rest of The World	143.96K	80.28K	-	-						-
Rest of The World Growth	79.32%	-	-	-						-
Total	4.64M	1.21M	132.06K	74.76K						2.77K
Total Growth	283.74%	815.26%	76.64%	-						-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 16, 2026

Data Sources Report a data error